Patents by Inventor Manfred Gerken
Manfred Gerken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230346949Abstract: A method of forming a conjugate of a sulfonamide and a polypeptide, the method comprising: a) Providing an activated sulfonamide, wherein the activated sulfonamide corresponds to Formula (I); b) Providing an aqueous solution of a polypeptide having a free amino group, wherein the aqueous solution optionally comprises an alcohol; c) Contacting the aqueous solution of b) with the activated sulfonamide of a); and d) Reacting the activated sulfonamide with the polypeptide having a free amino group, obtaining a solution comprising the conjugate of a sulfonamide and a polypeptide, wherein the sulfonamide is covalently bonded to the polypeptide. Also associated conjugates, processes, procedures, proinsulins and the like.Type: ApplicationFiled: December 10, 2020Publication date: November 2, 2023Inventors: Thomas BOEHME, Marisa RAEDISCH, Manfred GERKEN, Oliver STEYER, Oliver BOSCHEINEN, Daniel SCHEPS, Hermut WEHLAN
-
Patent number: 11560402Abstract: The invention relates to a method for the cleavage of a solid phase-bound polypeptide from the solid phase, the method comprising contacting the solid phase, to which the polypeptide is bound, with a composition consisting essentially of trifluoroacetic acid and 1,2-ethanedithiol, at a temperature in the range of about 23° C. to about 29° C.Type: GrantFiled: April 10, 2019Date of Patent: January 24, 2023Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Wolfgang Fiedler, Norbert Pleuss, Bernd Henkel, Manfred Gerken
-
Patent number: 11028123Abstract: The present invention relates to a method for the synthesis of a polypeptide comprising a pre-determined amino acid sequence. The method according to the invention comprises coupling cycles of coupling an N-terminally protected amino acid building block C-terminally at an unprotected N-terminal amino group of an amino acid chain, wherein at least one coupling cycle comprises a coupling step (a), a capping step (b), and a de-protecting step (c).Type: GrantFiled: April 10, 2019Date of Patent: June 8, 2021Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Bernd Henkel, Tobias Metzenthin, Manfred Gerken, Wolfgang Fiedler
-
Publication number: 20190330266Abstract: The invention relates to a method for the cleavage of a solid phase-bound polypeptide from the solid phase, the method comprising contacting the solid phase, to which the polypeptide is bound, with a composition consisting essentially of trifluoroacetic acid and 1,2-ethanedithiol, at a temperature in the range of about 23° C. to about 29° C.Type: ApplicationFiled: April 10, 2019Publication date: October 31, 2019Inventors: Wolfgang FIEDLER, Norbert PLEUSS, Bernd HENKEL, Manfred GERKEN
-
Publication number: 20190330263Abstract: The present invention relates to a method for the synthesis of a polypeptide comprising a pre-determined amino acid sequence. The method according to the invention comprises coupling cycles of coupling an N-terminally protected amino acid building block C-terminally at an unprotected N-terminal amino group of an amino acid chain, wherein at least one coupling cycle comprises a coupling step (a), a capping step (b), and a de-protecting step (c).Type: ApplicationFiled: April 10, 2019Publication date: October 31, 2019Inventors: Bernd Henkel, Tobias Metzenthin, Manfred Gerken, Wolfgang Fiedler
-
Patent number: 7803524Abstract: Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.Type: GrantFiled: March 21, 2005Date of Patent: September 28, 2010Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Stefan Brust, Stefan Knapp, Manfred Gerken, Lutz G. Guertler
-
Publication number: 20050271678Abstract: Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.Type: ApplicationFiled: March 21, 2005Publication date: December 8, 2005Applicant: Dade Behring Marburg GmbHInventors: Stefan Brust, Stefan Knapp, Manfred Gerken, Lutz Guertler
-
Patent number: 6869608Abstract: Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.Type: GrantFiled: December 4, 2001Date of Patent: March 22, 2005Assignee: Dade Behring Marburg GmbHInventors: Stefan Brust, Stefan Knapp, Manfred Gerken, Lutz G. Guertler
-
Patent number: 6602866Abstract: This invention discloses and claims a series of mercaptoacetylamide derivatives of formula I. Also disclosed and claimed are pharmaceutical compositions incorporating these compounds and processes for preparing said compounds.Type: GrantFiled: April 8, 2002Date of Patent: August 5, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Gary A. Flynn, Barbara A. Anderson, Manfred Gerken, Bernd Jablonka, Heinz-Werner Kleemann, Wolfgang Linz, Werner Seiz, Bernhard Seuring
-
Publication number: 20020193589Abstract: This invention discloses and claims a series of mercaptoacetylamide derivatives of formula I. Also disclosed and claimed are pharmaceutical compositions incorporating these compounds and processes for preparing said compounds. The use of said compounds for inhibition of the enzymes angiotensin converting enzyme and neutral endopeptidase, and for the treatment of hypertension and congestive heart failure are also disclosed and claimed.Type: ApplicationFiled: April 8, 2002Publication date: December 19, 2002Inventors: Gary A. Flynn, Barbara A. Anderson, Manfred Gerken, Bernd Jablonka, Heinz-Werner Kleemann, Wolfgang Linz, Werner Seiz, Bernhard Seuring
-
Publication number: 20020123039Abstract: Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.Type: ApplicationFiled: December 4, 2001Publication date: September 5, 2002Inventors: Stefan Brust, Stefan Knapp, Manfred Gerken, Lutz G. Guertler
-
Patent number: 6335158Abstract: The present invention is directed toward nucleic-acid based methodologies for the detection of human immunodeficiency virus (HIV) nucleic acids in a sample. A novel HIV-1 isolate, designated MVP5180/91, was isolated from a West African Cameroonian patient with immunodeficiency. Nucleic acid and amino acid sequence comparisons of this isolate, with other HIV-1 strains of subtypes A-E and HIV-2 isolates, demonstrated that this virus shares only limited homology with other known HIV-1 and -2 isolates. However, this virus does display some genetic relatedness to another Cameroonian isolate designated ANT-70. These viruses form the basis for a new HIV-1 group which has been designated subtype O. An immunologically important epitope, corresponding to amino acids 601-623 of the MVP5180/91 transmembrane envelope glycoprotein, was identified. Labeled nucleic acids can be prepared from the nucleotide sequence encoding this region and employed in standard hybridization assays to detect HIV-1 nucleic acids.Type: GrantFiled: August 10, 1998Date of Patent: January 1, 2002Assignee: Dade Behring Marburg GmbHInventors: Stefan Brust, Stefan Knapp, Manfred Gerken, Lutz G. Guertler
-
Publication number: 20010009667Abstract: Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.Type: ApplicationFiled: August 10, 1998Publication date: July 26, 2001Inventors: STEFAN BRUST, STEFAN KNAPP, MANFRED GERKEN, LUTZ G. GUERTLER
-
Patent number: 6020315Abstract: A preparation having increased in vivo tolerability comprising a glycosyl-Y[--C(.dbd.Y)--X--].sub.p --W(R).sub.n --X--C(.dbd.Y)-active compound, sugar or sugar alcohol and, optionally divalent ions, and a pharmaceutically tolerable carrier.Type: GrantFiled: May 13, 1998Date of Patent: February 1, 2000Assignee: Hoechst AktiengesellschaftInventors: Klaus Bosslet, Jorg Czech, Manfred Gerken, Rainer Straub, Matthias Blumrich
-
Patent number: 5935995Abstract: Compounds of the formula Iglycosyl-Y?--C(.dbd.Y)--X--!.sub.p --W(R).sub.n --Z--C(.dbd.Y)-active compound (I)are described which are suitable for the treatment of carcinomatous diseases, autoimmune diseases and chronic inflammatory diseases such as rheumatoid arthritis.Type: GrantFiled: March 11, 1997Date of Patent: August 10, 1999Assignee: Heochst AktiengesellschaftInventors: Klaus Bosslet, Jorg Czech, Manfred Gerken, Rainer Straub, Claude Monneret, Jean-Claude Florent, Frederic Schmidt
-
Patent number: 5830634Abstract: Immunologically active peptides which are derived from a novel immunodeficiency virus which has the designation MVP5180/91 are described. A diagnostic composition containing such a peptide and methods of detecting an antibody against a retrovirus that causes immune deficiency using such diagnostic composition are also described. A kit containing the immunologically active peptides is also described. An immunogen and method of immunizing a mammal against HIV infection using the immunologically active peptides is described. DNA encoding the peptides and methods of detecting nucleic acids encoding HIV viruses are also described.Type: GrantFiled: February 23, 1995Date of Patent: November 3, 1998Assignee: Dade Behring Marburg GmbHInventors: Stefan Brust, Stefan Knapp, Manfred Gerken, Lutz G. Guertler
-
Patent number: 5602108Abstract: Semisynthetic diastereomerically pure N-glycidylanthracyclines, a process for the stereoselective preparation thereof and the use thereof as cytostatics. The invention relates to anthracyclines having cytostatic activity and the formula I, which are, where appropriate, in the form of a salt with an inorganic or organic acid, ##STR1## in which R.sup.1 is hydrogen or a hydroxyl group,R.sup.2 is hydrogen, a hydroxyl group or an alkyloxy group (C.sub.1 -C.sub.4),R.sup.3 is hydrogen, a hydroxyl group or a structure of the formula II ##STR2## R.sup.4 is CH.sub.2 CH.sub.3, COCH.sub.3, COCH.sub.2 OH, CHOHCH.sub.3 or CHOHCH.sub.2 OH,R.sup.5 is hydrogen, a hydroxyl group, a methoxycarbonyl group or a structure of the formula II,R.sup.6 is hydrogen, an alkyl group (C.sub.1 -C.sub.4), an allyl group, a benzyl group or mono- or di-methyloxy-substituted benzyl group, a tetrahydropyranyl group,R.sup.7 is hydrogen, an alkyl group (C.sub.1 -C.sub.Type: GrantFiled: June 5, 1995Date of Patent: February 11, 1997Assignee: Behringwerke AktiengesellschaftInventors: Manfred Gerken, Monika Grimm, Ernst Raab, Dieter Hoffmann, Reiner Straub
-
Patent number: 5561119Abstract: Glycosylated prodrugs, a preparation method therefor, and their use with tumor-specific immunoenzymatic conjugates for the treatment of cancer, are described. These anthracycline prodrugs have formula (I).Type: GrantFiled: May 27, 1994Date of Patent: October 1, 1996Assignees: Laboratoires Hoechst, Behringwerke A.G.Inventors: Jean-Claude Jacquesy, Jean-Pierre Gesson, Claude Monneret, Martine Mondon, Brigitte Renoux, Jean-Claude Florent, Michel Koch, Fran.cedilla.ois Tillequin, Hans H. Sedlacek, Manfred Gerken, Cenek Kolar, Gilbert Gaudel, Klaus Bosslet, J org Czech, Dieter Hoffman, Gerhard Seemann, Hans-Ulrich Schorlemmer, Gerhard Dickneite
-
Patent number: 5260425Abstract: The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, ##STR1## which can optionally also be in the form of an acid addition salt of physiologically acceptable inorganic or organic acids, where R.sup.1 is hydrogen or a hydroxyl group, R.sup.2 is hydrogen, a hydroxyl or a methoxy group, R.sup.3 is hydrogen or a hydroxyl group, R.sup.4 is hydrogen or a hydroxyl group, R.sup.5 hydrogen, a hydroxyl or a methoxycarbonyl group, R.sup.6 is CH.sub.2 CH.sub.3, COCH.sub.3, COCH.sub.2 OH, CHOHCH.sub.3 or CHOHCH.sub.2 OH and R.sup.Type: GrantFiled: June 2, 1989Date of Patent: November 9, 1993Assignee: Behringwerke AktiengesellschaftInventors: Peter Hermentin, Ernst Raab, Cenek Kolar, Manfred Gerken, Dieter Hoffmann, Hans P. Kraemer, Ulrich Stache
-
Patent number: 4948880Abstract: The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I, which are optionally in the form of a salt of an inorganic or organic acid, ##STR1## in which the substituents have the following meaning: R.sup.1 is hydrogen or a hydroxyl group,R.sup.2 is hydrogen or a hydroxyl or a methoxy group,R.sup.3 is hydrogen or a hydroxyl group,R.sup.4 is hydrogen or a hydroxyl group,R.sup.5 is hydrogen, a hydroxyl or a methoxycarbonyl group, or a substituent of the general formula II, ##STR2## in which R.sup.8a has the meaning indicated for R.sup.8, or a substituent of the formula III, ##STR3## R.sup.6 is ethyl, methylcarbonyl, hydroxymethylcarbonyl, hydroxyalkyl or a dihydroxyalkyl,R.sup.7 is hydrogen or a substituent of the general formula IV, ##STR4## and R.sup.8 is hydrogen or a cyanomethyl group or a substituent of the general formula COR.sup.9 or CH.sub.2 R.sup.10, R.sup.9 being hydrogen, CH.sub.3, CF.sub.3 or CCl.sub.3, and R.sup.10 being C.sub.1 - to C.sub.Type: GrantFiled: December 4, 1987Date of Patent: August 14, 1990Assignee: Behringwerke AktiengesellschaftInventors: Peter Hermentin, Michael Paal, Hans P. Kraemer, Cenek Kolar, Dieter Hoffmann, Manfred Gerken, Hans G. Berscheid, Dirk Bottger